Determination of costs for the CSRwNP pathway. A time-driven activity-based costing experiment.

IF 2.1 4区医学 Q2 OTORHINOLARYNGOLOGY

Acta Otorhinolaryngologica Italica Pub Date : 2022-10-01 DOI:10.14639/0392-100X-N1937

Matteo Trimarchi, Emanuela Foglia, Fabrizio Schettini, Daniele Bellavia, Alessandro Vinciguerra, Paolo Petrone, Sara Torretta, Lorenzo Pignataro

{"title":"Determination of costs for the CSRwNP pathway. A time-driven activity-based costing experiment.","authors":"Matteo Trimarchi, Emanuela Foglia, Fabrizio Schettini, Daniele Bellavia, Alessandro Vinciguerra, Paolo Petrone, Sara Torretta, Lorenzo Pignataro","doi":"10.14639/0392-100X-N1937","DOIUrl":null,"url":null,"abstract":"Objectives: The study aims to define the economic resources needed to manage chronic rhinosinusitis with nasal polyposis (CRSwNP), assuming the hospital perspective, based on different patient characteristics, within a 24-month time horizon.Methods: Real-world data were collected in 3 Italian hospitals. A time-driven activity-based costing approach was implemented to map and assess the pathways for CRSwNP. The following drivers were considered: diagnostic services, drugs, consumables, human resources, equipment and overhead costs based on the length of stay. Costs related to management of comorbidities and adverse events were evaluated. Three main groups of patients were identified: ineligible for surgery; having 1 intervention; having more than 1 intervention. The economic absorption of patients who continued corticosteroid treatment was analysed.Results: Patients experiencing 1 intervention had a cost of 3,453.31 € that increased to 4,705.03 € for those who required additional surgery. The cost of intranasal corticosteroids was 649.20 €, whereas the cost of oral corticosteroids was 37.60 € per patient.Conclusions: The results demonstrate the strategic relevance of analytical cost definitions of the clinical pathway for CRSwNP, which can help to support decision makers in the review of internal procedures and in the definition of proper reimbursement tariffs.","PeriodicalId":6890,"journal":{"name":"Acta Otorhinolaryngologica Italica","volume":"42 5","pages":"450-457"},"PeriodicalIF":2.1000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Otorhinolaryngologica Italica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14639/0392-100X-N1937","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The study aims to define the economic resources needed to manage chronic rhinosinusitis with nasal polyposis (CRSwNP), assuming the hospital perspective, based on different patient characteristics, within a 24-month time horizon.

Methods: Real-world data were collected in 3 Italian hospitals. A time-driven activity-based costing approach was implemented to map and assess the pathways for CRSwNP. The following drivers were considered: diagnostic services, drugs, consumables, human resources, equipment and overhead costs based on the length of stay. Costs related to management of comorbidities and adverse events were evaluated. Three main groups of patients were identified: ineligible for surgery; having 1 intervention; having more than 1 intervention. The economic absorption of patients who continued corticosteroid treatment was analysed.

Results: Patients experiencing 1 intervention had a cost of 3,453.31 € that increased to 4,705.03 € for those who required additional surgery. The cost of intranasal corticosteroids was 649.20 €, whereas the cost of oral corticosteroids was 37.60 € per patient.

Conclusions: The results demonstrate the strategic relevance of analytical cost definitions of the clinical pathway for CRSwNP, which can help to support decision makers in the review of internal procedures and in the definition of proper reimbursement tariffs.

查看原文本刊更多论文

CSRwNP途径成本的确定。时间驱动的作业成本核算实验。

目的:本研究旨在确定治疗慢性鼻窦炎合并鼻息肉(CRSwNP)所需的经济资源，假设医院的角度，基于不同的患者特征，在24个月的时间范围内。方法:收集意大利3家医院的真实资料。采用时间驱动的基于作业的成本计算方法来绘制和评估CRSwNP的路径。考虑了下列驱动因素:诊断服务、药品、消耗品、人力资源、设备和基于住院时间的间接费用。评估与合并症和不良事件管理相关的费用。确定了三组主要患者:不适合手术;1次干预;干预次数超过一次。分析继续接受皮质类固醇治疗的患者的经济吸收情况。结果:接受一次干预的患者的费用为3,453.31欧元，而需要额外手术的患者的费用增加到4,705.03欧元。鼻内皮质类固醇的费用为649.20欧元，而口服皮质类固醇的费用为37.60欧元。结论:研究结果表明，CRSwNP临床路径的分析成本定义具有战略意义，有助于支持决策者审查内部程序和确定适当的报销费率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Otorhinolaryngologica Italica OTORHINOLARYNGOLOGY-

CiteScore

3.40

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Acta Otorhinolaryngologica Italica first appeared as “Annali di Laringologia Otologia e Faringologia” and was founded in 1901 by Giulio Masini. It is the official publication of the Italian Hospital Otology Association (A.O.O.I.) and, since 1976, also of the Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale (S.I.O.Ch.C.-F.). The journal publishes original articles (clinical trials, cohort studies, case-control studies, cross-sectional surveys, and diagnostic test assessments) of interest in the field of otorhinolaryngology as well as clinical techniques and technology (a short report of unique or original methods for surgical techniques, medical management or new devices or technology), editorials (including editorial guests – special contribution) and letters to the Editor-in-Chief. Articles concerning science investigations and well prepared systematic reviews (including meta-analyses) on themes related to basic science, clinical otorhinolaryngology and head and neck surgery have high priority.